A detailed history of Barclays PLC transactions in Amneal Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 296,384 shares of AMRX stock, worth $2.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
296,384
Previous 296,384 -0.0%
Holding current value
$2.57 Million
Previous $2.47 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$6.42 - $8.83 $1.09 Million - $1.5 Million
169,756 Added 134.06%
296,384 $2.47 Million
Q2 2024

Aug 14, 2024

SELL
$5.36 - $7.11 $164,814 - $218,625
-30,749 Reduced 19.54%
126,628 $804,000
Q1 2024

May 15, 2024

SELL
$5.24 - $6.34 $391,129 - $473,236
-74,643 Reduced 32.17%
157,377 $953,000
Q4 2023

Feb 15, 2024

BUY
$3.36 - $6.21 $590,862 - $1.09 Million
175,852 Added 313.08%
232,020 $1.41 Million
Q3 2023

Nov 07, 2023

SELL
$2.76 - $4.59 $8,222 - $13,673
-2,979 Reduced 5.04%
56,168 $236,000
Q2 2023

Aug 03, 2023

SELL
$1.33 - $3.1 $37,035 - $86,322
-27,846 Reduced 32.01%
59,147 $183,000
Q1 2023

May 04, 2023

BUY
$1.27 - $2.7 $31,052 - $66,017
24,451 Added 39.1%
86,993 $120,000
Q4 2022

Feb 13, 2023

BUY
$1.96 - $2.61 $45,640 - $60,776
23,286 Added 59.32%
62,542 $124,000
Q3 2022

Nov 03, 2022

SELL
$2.02 - $3.62 $51,366 - $92,052
-25,429 Reduced 39.31%
39,256 $79,000
Q2 2022

Aug 12, 2022

SELL
$3.01 - $4.46 $3,190 - $4,727
-1,060 Reduced 1.61%
64,685 $205,000
Q1 2022

May 16, 2022

SELL
$3.9 - $4.89 $465,184 - $583,269
-119,278 Reduced 64.47%
65,745 $273,000
Q4 2021

Feb 14, 2022

BUY
$3.95 - $5.85 $469,220 - $694,921
118,790 Added 179.35%
185,023 $886,000
Q3 2021

Nov 09, 2021

BUY
$4.31 - $5.64 $180,063 - $235,627
41,778 Added 170.84%
66,233 $354,000
Q2 2021

Aug 13, 2021

SELL
$5.12 - $6.82 $484,930 - $645,942
-94,713 Reduced 79.48%
24,455 $124,000
Q1 2021

May 13, 2021

BUY
$4.74 - $7.38 $61,852 - $96,301
13,049 Added 12.3%
119,168 $802,000
Q4 2020

Feb 11, 2021

SELL
$3.95 - $5.42 $97,249 - $133,440
-24,620 Reduced 18.83%
106,119 $485,000
Q3 2020

Nov 12, 2020

SELL
$3.54 - $5.27 $48,565 - $72,299
-13,719 Reduced 9.5%
130,739 $508,000
Q2 2020

Aug 12, 2020

BUY
$2.87 - $5.46 $58,783 - $111,831
20,482 Added 16.52%
144,458 $688,000
Q1 2020

May 13, 2020

SELL
$2.46 - $5.35 $39,773 - $86,498
-16,168 Reduced 11.54%
123,976 $431,000
Q4 2019

Feb 10, 2020

BUY
$2.65 - $5.56 $190,935 - $400,603
72,051 Added 105.81%
140,144 $676,000
Q3 2019

Nov 14, 2019

SELL
$2.29 - $7.1 $461,540 - $1.43 Million
-201,546 Reduced 74.75%
68,093 $198,000
Q2 2019

Aug 14, 2019

BUY
$6.44 - $14.29 $1.36 Million - $3.02 Million
211,562 Added 364.28%
269,639 $1.93 Million
Q1 2019

May 15, 2019

BUY
$11.87 - $14.84 $673,634 - $842,184
56,751 Added 4279.86%
58,077 $823,000
Q4 2018

Feb 14, 2019

SELL
$13.09 - $21.49 $544,871 - $894,521
-41,625 Reduced 96.91%
1,326 $18,000
Q3 2018

Nov 14, 2018

SELL
$16.4 - $24.27 $5.33 Million - $7.89 Million
-325,205 Reduced 88.33%
42,951 $953,000
Q2 2018

Aug 14, 2018

BUY
$13.95 - $20.2 $5.14 Million - $7.44 Million
368,156 New
368,156 $6.04 Million

Others Institutions Holding AMRX

About Amneal Pharmaceuticals, Inc.


  • Ticker AMRX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 151,408,992
  • Market Cap $1.31B
  • Description
  • Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and comme...
More about AMRX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.